AstraZeneca: Urinary Bladder Neoplasms trials

The registry lists 20 Urinary Bladder Neoplasms studies with AstraZeneca as lead sponsor. 5 are open to participants now and 4 have results posted.

Phase 1 5Phase 2 7Phase 3 4Phase 4 1No phase 6(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingNCT07876817Phase 4
• An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCRecruitingNCT07720284Phase 3
• DESTINY-PANTUMOUR04RecruitingNCT07124000
• TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian FederationRecruitingNCT07038928
• Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)RecruitingNCT06960577Phase 2
• A First-in-human Study to Evaluate the Safety and Tolerability of AZD8853 in Participants With Selected Advanced/Metastatic Solid TumoursTerminatedNCT05397171Phase 1/2Results posted
• Durvalumab+ Gemcitabine/Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBCActive, not recruitingNCT03732677Phase 3Results posted
• A Study of Durvalumab Alone and Durvalumab+Olaparib in Advanced, Platinum-Ineligible Bladder Cancer (BAYOU)Active, not recruitingNCT03459846Phase 2Results posted
• A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder CancerCompletedNCT00661609Phase 2Results posted
• ESPERANZA: External Control Arm Study for T-DXd for Patients With HER2 IHC3+ Solid TumorsCompletedNCT06973161
• Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDERCompletedNCT05945108
• A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid TumoursTerminatedNCT05363605Phase 1/2
• Treatment Combination of Durvalumab, Tremelimumab and Enfortumab Vedotin or Durvalumab and Enfortumab Vedotin in Patients With Muscle Invasive Bladder Cancer Ineligible to Cisplatin or Who Refuse CisplatinActive, not recruitingNCT04960709Phase 3
• Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid MalignanciesActive, not recruitingNCT04644068Phase 1/2
• Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial CancerActive, not recruitingNCT03682068Phase 3
• An Epidemiologic Study on PD-L1 Expression Combined With Clinical Observation in the Chinese MIUBC Patients.CompletedNCT03433924
• Cancer in Patients on Dapagliflozin and Other Antidiabetic TreatmentCompletedNCT02695121
• Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Phase 1b Study in Pts w/ Muscle Invasive Bladder CancerActive, not recruitingNCT02546661Phase 1
• Phase I Open Label Dose Escalation Study to Investigate the Safety & Pharmacokinetics of AZD5312 in Patients With Androgen Receptor TumorsCompletedNCT02144051Phase 1
• Phase II Gemcitabine + Cisplatin +/- Iressa Bladder CCTCompletedNCT00246974Phase 2